ArticleJournal of pharmaceutical health care and sciences2024
Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.
Ryo Takada et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.